The Industry Leading Platform for Digitalized Clinical Development
MAKE YOUR PLANS TO ATTEND:
Tuesday September 21, 2021 @ 5:05pm. Bio IT World. Virtual or Boston Sheraton
Digitalized Clinical Development – Save $8,000,000 and 8 Months on a Typical Phase 3 Study
Barrie Nelson, Vice President, Digital Clinical Innovation & Chief Standards Officer, Nurocor
Executives responsible for Clinical Operations face increasing pressures to reduce costs, meet ever aggressive timelines and improve productivity of Trial Execution Teams. The Nurocor automation solution saves, conservatively, $8,000,000 and 8 months on a typical Phase 3 trial. The Nurocor solution provides quality by design planning and execution, maximizing the value of existing systems through built-in connectivity, and enables high value staff to focus on critical tasks, not the mundane.
Digitalized Clinical Development
Digitalized Clinical Development presents opportunities for automation and standardization.
Innovative Clinical Development Organizations (CDOs) take advantage of standards during the planning stage, the earliest point in the development process. Standardization of protocol elements, introduction of an end-to-end process for clinical development standards and the utilization of TransCelerate’s Common Protocol Template (CPT), coupled with the right technology, provide a platform for planning and executing trials more efficiently with a goal of getting products to market sooner.
Nurocor provides a set of documented data standards, has defined the Lean Protocol™ Process, and automates the application of these standards and the Lean Protocol with the Nurocor Clinical Platform.
Nurocor provides the industry-leading platform for Digitalized clinical development to help companies bring drugs to market faster. Automating the Nurocor Lean Protocol™ with the Nurocor Clinical Platform delivers a front-loaded, workflow-driven, digital process enabling the parallelization of multiple steps to significantly reduce the time required for clinical development.
For more information, please